\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes Health Culture and society Security Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment Horizon EuropeThe COM has informed the following:
The current problems in the submission system are mainly due to the extremely high traffic that the system currently suffers in conjunction with an unfortunate chain of incidents linked to the global infrastructure that supports it.
Main incidents reported:
It is essential that participants take screenshots before the call deadline and if submission did not succeed, submit a complaint within four days after the call deadline
Instructions are given in the online manual
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Horizon Europe Digital Europe
Building on the revised Charter for access to research infrastructures , this new Charter will be specifically aimed at facilitating access of companies. It will make it easier for companies, especially small and medium-sized businesses (SMEs), startups and scaleups, to access Europe’s world-class research and technology... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
